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Abstract. Phytoestrogens exert protective effects on the cardio-
vascular system through mechanisms that have yet to be clearly 
demonstrated. The aim of this study was to evaluate the protec-
tive effects exerted by genistein on cardiomyoblasts (H9c2) 
against oxidative stress, nitric oxide (NO) release, viability, 
proliferation/migration and mitochondrial function. H9c2 
cultured in physiological or peroxidative conditions, were treated 
with genistein in the absence or presence of estrogen recep-
tors (ERs), G protein- coupled-estrogenic-receptors (GPER), 
Akt, extracellular- signal-regulated kinases 1/2 (ERK1/2) and 
p38 mitogen activated protein kinase (p38MAPK) blockers. cell 
viability, proliferation, migration, mitochondrial membrane 
potential, mitochondrial oxygen consumption and oxidant/anti-
oxidant system, were measured by specific assays. Western 
blot assay was used for the analysis of NO synthase (NOS) 
subtypes' and expression and activation of various kinases. In 
all experiments 17β-estradiol was used for comparison. The 
results showed that phytoestrogens and estrogens can increase 
cell viability, proliferation/migration and improve mitochon-
drial membrane potential and oxygen consumption of H9c2. 
Furthermore, NO release was modulated by genistein and 
17β-estradiol. These effects were reduced or abolished by the 
pre-treatment with ERs, GPER, Akt, ERK1/2 and p38MAPK 
blockers. Finally, a reduction of reactive oxygen species 
production and an increase of glutathione content was found in 
response to the two agents. In H9c2 cultured in physiological 
conditions, genistein induced endothelial NOS-dependent NO 
production through the involvement of estrogenic receptors 
and by the modulation of intracellular signalling related to Akt, 
ERK1/2, and p38MAPK. Moreover, estrogens and phytoes-
trogens protected H9c2 against oxidative stress by reducing 
inducible NOS expression and through the modulation of the 
antioxidant system and mitochondrial functioning.
Introduction
It is widely accepted that oxidative stress may represent one 
characteristic feature in the pathological progress of cardiac 
damage by affecting dNA, lipids and proteins, in addition to 
activating a redox-regulated signalling cascade that ultimately 
leads to cell death (1). Since mitochondria are the main target 
of reactive oxygen species (ROS) production and damage (2), 
the modulation of mitochondrial dysfunction could assume 
clinical relevance in the prevention of heart disease.
Nitric oxide (NO) has been reported to play either a benefi-
cial or harmful role in the control of cardiovascular system, 
depending on the dose and duration of exposure (3). On the 
one hand, the blocking of NO production via endothelial NO 
synthase (eNOS) would abolish the cardioprotection against 
ischemia/reperfusion injury (4). On the other hand, inducible 
NOS (iNOS)-dependent NO production could be detrimental 
for cardiac function (5,6) through augmented formation of 
peroxinitrites.
Thus, the modulation of mitochondria activity and NO 
release could represent a therapeutic tool for the management 
of cardiac disease. Genistein, the main soy‑derived isoflavone 
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with a multitude of health benefits (7), has been reported to 
exert protective effects on the cardiovascular system through its 
antioxidant and anti‑inflammatory function (8), which would be 
related to both mitochondria and NO. Hence, in human aortic 
and porcine coronary endothelial cells, genistein enhanced 
eNOS expression and augmented NO synthesis (9-11). In addi-
tion, the opposite effects of genistein on iNOS/eNOS-related 
NO release were found to be associated with its beneficial 
role against isoproterenol-induced cardiac hypertrophy (12). 
It is also notable that in different cell types, genistein was 
able to counteract the damage caused by peroxidation by 
preserving mitochondrial function (13,14). Mechanisms 
related to extracellular signal-regulated kinases 1/2 (ERK1/2), 
mitogen-activated protein kinase (MAPK) and Akt intracel-
lular pathways have been reported to be involved in the above 
effects (15).
Although there is extensive literature about the cardio-
vascular effects elicited by genistein, data concerning its 
function on cardiac cells remain scarce. Thus, in this study we 
examined the effects of genistein on cardiomyoblast viability, 
proliferation/migration and mitochondrial function in both 
physiological and peroxidative conditions and analyzed 
the involvement of eNOS/iNOS-dependent NO release and 
ERK1/2, p38MAPK and Akt pathways. Since genistein has 
gained clinical consideration for the management of post-
menopausal symptoms, due to its molecular structure that 
resembles that of estrogens, its effects were compared with 
those elicited by 17β-estradiol.
Materials and methods
Culture of H9C2. Rat cardiomyoblasts (H9c2) were obtained 
from the American Type culture collection (ATcc; cat. 
no. CRL‑1446) and cultured in Dulbecco's modified Eagle's 
medium (dMEM; Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (FBS; Euroclone), 2 mM L-glutamine 
(Sigma-Aldrich) and 1% penicillin-streptomycin (Sigma-
Aldrich) at 37˚C with 5% CO2 in an incubator. For NO 
measurement, 7,500 cells/well were plated in 96-well plates 
with dMEM 0% FBS supplemented with 1% penicillin-strep-
tomycin-glutamine and without phenol red (starvation 
medium, Sigma-Aldrich) for 4-6 h. Mitochondrial membrane 
potential and cell viability were also measured, following the 
same procedure used for NO measurement, but with plating 
of 1x104 cells/well. For ROS quantification, 2.5x104 cells/well 
were plated in 96-wells. For Trypan Blue test and western 
blot analysis, 4x105 cells/well were plated in 6-well plates in 
complete medium, and at 80% confluency at least, they were 
incubated with starvation medium overnight. Each experi-
mental protocol was repeated in five different cell samples.
NO release. The NO production was measured in H9c2 
culture supernatants using the Griess method (Promega; 
cat. no. G2930) as previously performed in the same or 
similar cellular models (16-20). H9c2 cardiomyoblasts were 
treated for 30 min with genistein (10 pM, 100 pM, 10 nM, 
100 nM and 1 µM; Sigma-Aldrich; cat. no. G6649) and 
17β-estradiol (10 pM, 100 pM, 10 nM, 100 nM and 1 µM; 
Sigma-Aldrich; cat. no. E8875). In addition, some samples 
were stimulated with the NOS blocker, Nω-nitro-L-arginine 
methylester (L-NAME; 10 mM; Sigma-Aldrich), the p38 
MAPK inhibitor, SB203580 (100 nM; Sigma-Aldrich), the 
phosphatidylinositol 3'-kinase (PI3K) inhibitor, wortmannin 
(100 nM; Sigma-Aldrich), the MAPK/ERK inhibitor, UO126 
(100 nM; Sigma-Aldrich), the associated estrogen receptors 
(ERs) inhibitor, fulvestrant (100 nM; Sigma-Aldrich), and 
the G protein-coupled estrogenic receptors (GPER) inhibitor, 
G15 (100 nM; Sigma-Aldrich), which were administered for 
30 min prior to genistein (100 nM) and 17β-estradiol (100 nM). 
Those inhibitors were also administered alone at the above 
reported concentrations, to H9c2 for 30 min. In addition, in 
some experiments the effects of genistein and 17β-estradiol 
were examined in peroxidative conditions obtained by using 
hydrogen peroxide. In particular, 200 µM hydrogen peroxide 
was administered for 30 min after the 30 min-pretreatment of 
H9c2 with genistein (100 nM) and 17β-estradiol (100 nM) 
and the effects on NO release were examined. At the end of 
the stimulations, NO production in the sample's supernatants 
was examined by adding an equal volume of Griess reagent 
following the manufacturer's instructions. At the end of incu-
bation, absorbance at 570 nm was measured by a spectrometer 
(VIcTOR™ X Multilabel Plate Reader; PerkinElmer) and the 
role of NO production in this step was examined. The value of 
each sample was quantified in respect to nitrite standard curve 
and expressed as nitrite production (µM).
Cell viability. Oxidative stress was generated in H9c2 through 
200 µM hydrogen peroxide for 30 min in starvation medium. 
cell viability was examined using the 1% 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT; 
Life Technologies Italia; cat. no. cT02) dye, as previously 
described (16-20). H9c2 cardiomyoblasts were treated in 
physiological and peroxidative conditions with genistein 
(10 pM, 100 pM, 10 nM, 100 nM and 1 µM, for 30 min; Sigma-
Aldrich) and 17β-estradiol (10 pM, 100 pM, 10 nM, 100 nM 
and 1 µM, for 30 min; Sigma-Aldrich), in the presence or 
absence of the same inhibitors used in Griess assay. The same 
experimental protocol described for NO release, with regard 
to estrogen/phytoestrogens alone or in the presence/absence 
of inhibitors in physiologic and peroxidative conditions, was 
followed. After each treatment, the medium was removed, and 
fresh culture medium without red phenol and FBS and with 
MTT dye was added in 96-well plates containing the cells 
and incubated for 2 h at 37˚C. Thereafter, the fresh culture 
medium without red phenol and FBS was removed, and an 
MTT solubilization solution (dimethyl sulfoxide; dMSO; 
Sigma-Aldrich) in equal volume to the original culture 
medium was added and mixed in a gyratory shaker until the 
complete dissolution of formazan crystals. cell viability was 
determined by measuring the absorbance through a spectrom-
eter (VIcTOR™ X Multilabel Plate Reader; PerkinElmer) 
with a wavelength of 570 nm and cell viability was calculated 
by setting control cells as 100%.
Mitochondrial membrane potent ial measurement. 
Mitochondrial membrane potential measurement in H9c2 
was performed with Jc-1 assay. cells were stimulated as 
described for cell viability. After stimulations, the medium of 
cells plated in starvation medium was removed and incubated 
with 5,51,6,61-tetrachloro-1,11,3,31 tetraethylbenzimidazolyl 
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carbocyanine iodide (Jc-1) 1X diluted in 1X Assay Buffer  for 
15 min at 37˚C in an incubator, following the manufacturer's 
instructions (cayman chemical; cat. no. 10009172) and as 
previously performed (13,16,18). After incubation, the cells 
were washed twice with 1X Assay Buffer  and then the mito-
chondrial membrane potential was determined by measuring 
the red (excitation 550 nm/emission 600 nm) and green 
(excitation 485 nm/emission 535 nm) fluorescence through 
a spectrometer (VIcTOR™ X Multilabel Plate Reader; 
PerkinElmer). To identify cells undergoing apoptosis, the ratio 
of fluorescent intensity of J‑aggregates to fluorescent intensity 
of monomers was used as an indicator of cell health.
Wound‑healing migration assay. cell migration was evaluated 
by the in vitro scratch assay in serum‑starved cells. Briefly, 
cell monolayers were mechanically scratched with a sterile 
yellow tip (diameter=2 mm) along the center of the plate and 
cell debris was removed by gentle washing with PBS. Some 
samples were treated with genistein (10 pM, 100 nM) and 
17β-estradiol (10 pM, 100 nM) for 24 h and 48 h. Images of 
cell monolayers were taken using an optical microscope (Leica 
Icc50Hd) with a digital camera to evaluate wound closure. 
Migration was quantified by calculating the area of wound at 
time points T0 (time of wound), T24 (24 h after wound) and 
T48 (48 h after wound) by using ImageJ software (National 
Institutes of Health). For each condition, the percentage of 
wound closure at several time points throughout the course 
of the assay, was obtained through the formula: % wound 
closure: [WA0‑WA/WA0]*100, where WA is the wound area 
and WA0 is the original size of the wound area. Experiments 
were conducted in triplicate and repeated at least five times.
Trypan blue proliferation assay. cell proliferation was evalu-
ated with Trypan blue exclusion method. cells were stimulated 
as described for cell viability and mitochondrial membrane 
potential but with 24 h of stimulation and without blockers. At 
the end of the stimulation, the cells were detached and 50 µl 
cell suspension was diluted 1:2 with Trypan blue and mixed by 
pipetting up and down and then, 10 µl was put in the Burker 
chamber for cell counting. Blue cells were the non-viable cells.
The percentage of viable cells was calculated by dividing 
the number of viable cells by the number of total cells and 
multiplying by 100%.
Glutathione (GSH) quantification. GSH measurement 
was performed with a specific kit (cayman chemical; 
cat. no. 703002) as previously described (13,16,20). H9c2 
cardiomyoblasts were treated in peroxidative conditions with 
genistein (10 pM, 100 nM) and 17β-estradiol (10 pM, 100 nM) 
for 30 min, in the presence of 200 µM hydrogen peroxide. The 
antioxidant 200 µM N acetyl-cysteine (NAc; Sigma-Aldrich), 
administered for 30 min, was used as the positive control. 
After treatments, the cells were lysed using the 50 mM 
2-(N-morpholino) ethanesulphonic acid (GSH MES Buffer) 
and a rubber policeman. The cell pellet was centrifuged at 
10,000 x g for 15 min at 4˚C. After centrifugation, the super-
natant was treated with an equal volume of metaphosphoric 
acid (final concentration 5%; Sigma‑Aldrich) for 5 min and 
centrifuged at 2,000 x g for at ≥2 min. The supernatant was 
collected and supplemented with 50 µl per ml of 4 M solution 
of triethanolamine (Sigma-Aldrich). Then, 50 µl of the samples 
was transferred to a 96-well plate where GSH was detected 
following the manufacturer's instructions through a spectrom-
eter (VIcTOR™ X Multilabel Plate Reader; PerkinElmer) 
at excitation/emission wavelengths of 405-414 nM. GSH was 
expressed as nanomoles in samples with 1.5 mg of protein/ml.
ROS quantif ication. The oxidation of 2,7-dichlo-
rodihydrof luorescein d iacetate (H2dcFdA) into 
2,7‑dichlorodihydrofluorescein (DCF) was used to assess ROS 
generation, following the manufacturer's instructions (Abcam; 
cat. no. ab113851). Briefly, the cells in 96‑well plates were 
stimulated with 30 min 200 µM hydrogen peroxide alone or in 
the presence of genistein (10 pM, 100 pM, 10 nM, 100 nM and 
1 µM; for 30 min) and 17β-estradiol (10 pM, 100 pM, 10 nM, 
100 nM and 1 µM; for 30 min). The antioxidant 200 µM NAc 
was used as the positive control. After treatments, the reactions 
were stopped by removing the medium and washing with phos-
phate-buffered saline (PBS) followed by staining with 10 µM 
H2DCFDA for 20 min at 37˚C. The fluorescence intensity of 
dcF was measured at an excitation and emission wavelength 
of 485 and 530 nm by using a spectrophotometer (VIcTOR™ 
X Multilabel Plate Reader; PerkinElmer) (13,16,18).
Oxygen consumption rate (OCR) assay. Oxygen consump-
tion rate assay kit (MitoXpress-Xtra HS Method) (cayman 
chemical; cat. no. 600800) was used to assess the OcR, which 
is considered a parameter to study mitochondrial function. 
Briefly, cells in the 96‑well plates were stimulated with 30 min 
200 µM hydrogen peroxide alone or in the presence of genistein 
(10 pM and 100 nM; for 30 min) and 17β-estradiol (10 pM and 
100 nM; for 30 min). At the end of stimulation, 10 µM of the 
probe (MitoXpress-Xtra Solution) was added in each well. The 
plate was read at 380 nm with a spectrophotometer (VIcTOR™ 
X Multilabel Plate Reader; PerkinElmer). The results corre-
spond to the lifetime of the probe expressed in µs, calculated 
using the formula: Lifetime (µs): (70-30)/ln (W1/W2) in which 
W1 and W2 represent window 1 and 2, respectively, for the 
measured intensity readings at each time point; 70 and 30 
represent the delay time of W1 and W2.
Cell cycle analysis, by using propidium iodide stain.  Flow 
cytometry was used for cell cycle analysis. This technique is 
widely used for measuring all phases of cell cycle including 
apoptosis (21). H9c2 cells (400,000 cells/well in 6-well plate), 
were stimulated with genistein (10 pM and 100 nM; for 24 h) 
and 17β-estradiol (10 pM and 100 nM; for 24 h) alone, or in the 
presence of 200 µM hydrogen peroxide. The effects of 200 µM 
hydrogen peroxide for 30 min alone were also examined. At 
the end of each stimulation, the culture medium was collected 
from each well and transferred in a 15 ml tube in order to collect 
the cells that eventually detached. cells were detached with 
trypsin-EdTA thereafter, an appropriate volume of culture 
medium was added, and cell suspension was transferred to a 
tube and centrifuged at 900 x g for 5 min at room temperature. 
The supernatant was discarded, and cells were fixed in 1 ml 
70% ethanol for 1 h at ‑20˚C. After 1 h, the cells were centri-
fuged at 900 x g for 5 min at room temperature, and ethanol 
as well as the supernatant were discarded. cells were washed 
with PBS and centrifuged again 900 x g for 5 min at room 
FARRUGGIO et al:  PROTEcTIVE EFFEcTS OF PHYTOESTROGENS IN cARdIOMYOBLASTS 2301
temperature. Each pellet of cells was resuspended in 200 µl 
propidium iodide buffer (3.4 mM trisodium citrate, 9.65 mM 
sodium chloride, 0.003% tergitol), 25 µl RNase A (10 ng/ml; 
cabru), and 10 µl propidium iodide (1 mg/ml; cabru).
Then, 50 µl of each sample was transferred in a 96-well 
plate in triplicate, and after 15 min at 37˚C in the dark, the 
analysis was performed using Attune NxT (Life Technologies).
Cell lysates. The H9C2 at confluence were plated in starvation 
medium overnight at 37˚C with 5% CO2. Western blot analysis 
was performed in H9c2 treated with genistein (10 pM and 
100 nM for 30 min) and 17β-estradiol (10 pM and 100 nM for 
30 min) in the presence or absence of specific inhibitors, as 
described previously, for NO release and cell viability. In some 
samples, the effects of 200 µM hydrogen peroxide, adminis-
tered for 30 min after the 30 min-pretreatment with 100 nM 
phytoestrogens/estrogens, were also examined. Some samples 
of 200 µM hydrogen peroxide were administered 30 min after 
phytoestrogens/estrogens. At the end of stimulation, H9c2 
cardiomyoblasts were lysed in iced Ripa buffer supplemented 
with sodium orthovanadate (2 mM; Sigma-Aldrich) and 
protease inhibitors cocktail (1 mM; Thermo Fisher Scientific) 
and phenylmethanesulfonyl fluoride (1 mM; Sigma‑Aldrich). 
The extracted proteins were quantified through bicinchoninic 
acid protein (BcA; Pierce) and used for electrophoresis and 
immunoblotting studies.
Western blot analysis. cell lysates (30 µg protein each 
sample) were dissolved in 5X Laemmli buffer, boiled for 
5 min and resolved in 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis gels (Bio-Rad Laboratories). 
After electrophoresis they were transferred to polyvinylidene 
fluoride membranes (Bio-Rad Laboratories), which were 
incubated overnight at 4˚C with specific primary antibodies: 
Anti phospho-eNOS (1:1,000; Ser1177, cell Signaling 
Technologies; cat. no. 9570), anti eNOS (1:1,000; cell Signaling 
Technologies, cat. no. 32027), anti iNOS (1:500; Santa cruz 
Biotechnology, cat. no. sc-7271), anti phospho-Akt (1:1,000; 
Ser473, Santa cruz Biotechnology, cat. no. sc-33437), anti 
Akt (1:1,000; Santa cruz Biotechnology, cat. no. sc-81434), 
anti phospho-ERK1/2 (1:1,000; Thr202/Tyr204, Santa cruz 
Biotechnology, cat. no. sc-16982), anti ERK1/2 (1:1,000; cell 
Signaling Technologies, cat. no. 9102), anti phospho-p38 
MAP Kinase (1:1,000; Thr180/Tyr182, cell Signaling 
Technologies, cat. no. 9211), and anti p38 MAP Kinase 
(1:1,000; cell Signaling Technologies, cat. no. 9212). The 
membranes were washed and then incubated with horseradish 
peroxidase-coupled goat anti-rabbit IgG (Sigma-Aldrich), 
peroxidase-coupled rabbit anti-goat IgG and horseradish 
peroxidase-coupled goat anti-mouse IgG (Sigma-Aldrich) for 
45 min and were developed through a non-radioactive method 
using Western Lightning Chemiluminescence (PerkinElmer 
Life and Analytical Sciences). Phosphorylated protein expres-
sion was calculated as a ratio towards specific total protein 
expression or β-actin (1:5,000; Santa cruz Biotechnology; cat. 
no. sc-47778) detection.
Statistical analysis. All data were recorded using the Institution's 
database. Statistical analysis was performed using STATVIEW 
version 5.0.1 for Microsoft Windows (SAS Institute Inc.) 
and GraphPad Prism 6 (San diego). data were checked for 
normality prior to statistical analysis. All the results obtained 
were examined through one-way ANOVA followed by Tukey's 
test, by comparing preselected pairs of column means. Pearson's 
coefficient was calculated for linear correlation analysis in 
dose-response studies. data are presented as means ± standard 
deviation (SD) of five independent experiments for each experi-
mental protocol. P<0.05 was considered statistically significant.
Results
Effects of genistein and 17β‑estradiol on cell viability, 
proliferation/migration and mitochondrial membrane 
potential in the presence/absence of various inhibitors. As 
shown in Fig. 1A, in physiological conditions genistein and 
17β-estradiol increased cell viability in a dose-dependent 
manner up to 100 nM. At all doses genistein and 17β-estradiol 
improved the mitochondrial membrane potential (Fig. 1c). 
Furthermore, genistein and 17β-estradiol counteracted the 
effects of 200 µM hydrogen peroxide on cell viability (Fig. 1B) 
and mitochondrial membrane potential (Fig. 1d). Moreover, 
both agents were able to increase cell proliferation in physi-
ological (Fig. 2A) and peroxidative (Fig. 2B) conditions and 
increased cell migration (Fig. 2c and Fig. S1) up to 24 h from 
the beginning of the stimulation. The above effects were partly 
confirmed by the cell cycle analysis. Thus, in physiological 
conditions, genistein increased the percentage of H9c2 in 
G0/G1, S and G2/M phase (Figs. 3A and S2A). As regarding 
estradiol, both 10 pM and 100 nM were able to improve G0/G1 
and G2/M phases (Figs. 3A and S2A). In the peroxidative 
conditions, both genistein and 17β-estradiol reduced apoptosis 
at all doses. In comparison with hydrogen peroxide, 100 pM 
and 100 nM genistein and 10 pM and 100 nM estradiol were 
able to increase the percentage of H9c2 in G0/G1. doses of 
genistein and 17β-estradiol increased the percentage of H9c2 
in S and G2/M phase, as well (Figs. 3B and S2B).
Of note is that, the effects of genistein and 17β-estradiol 
on cell viability (Fig. 4) and mitochondrial membrane 
potential (Fig. S3) were reduced or abolished by fulvestrant, 
G15, L-NAME, UO126, wortmannin and SB203580. The 
involvement of eNOS, iNOS, Akt, ERK1/2 and p38 MAPK 
was confirmed by western blot analysis of their expression or 
activation. Thus, in the physiological conditions, both genis-
tein and 17β-estradiol increased eNOS, Akt, ERK1/2 and p38 
MAPK activation (Figs. 5A, S4A and S4c, S5A and S5c, 
S6A and S6c, S7A and S7c), while causing either no effects 
or a slight decrease of iNOS expression at 100 nM (Figs. 5B, 
S8A and S8c).
In H9c2 stimulated with hydrogen peroxide, eNOS, Akt, 
ERK1/2 and p38 MAPK activation was reduced (Figs. 5A, 
S4B and S4d, S5B and S5d, S6B and S6d, S7B and S7d) 
whereas iNOS expression was increased in comparison with 
control (Figs. 5B, S8B and S8d). Notably, the pretreatment 
with genistein and 17β-estradiol counteracted the inhibition of 
eNOS (Figs. 5A, S4B and S4d) and the increased expression 
of iNOS (Figs. 5B, S8B and S8d). All inhibitors were able 
to prevent the effects of genistein and 17β-estradiol both in 
physiological and peroxidative conditions (Figs. S4-S8).
The protective effects elicited by genistein and 17β-estradiol 
against oxidative stress were confirmed by the finding of a 
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reduction of intracellular ROS release (Fig. 6A) and an increase 
of GSH production (Fig. 6B).
Effects of genistein and 17β‑estradiol on mitochondrial 
oxygen consumption. As shown in Fig. 6c, both genistein 
and 17β-estradiol increased mitochondrial oxygen consump-
tion in H9c2-cultured physiological conditions at any doses. 
Moreover, they were able to counteract the effects of hydrogen 
peroxide.
Effects of genistein and 17β‑estradiol on NO release. As 
shown in Fig. 7A, in physiological conditions genistein and 
17β-estradiol increased NO release with a maximum effect at 
100 nM. Both agents were able to counteract the effects of 
hydrogen peroxide on NO release (Fig. 7B).
Fig. 7c and d shows that, the presence of various inhibi-
tors, the effects of genistein and 17β-estradiol on NO release 
by H9c2 cultured in physiological and peroxidative conditions 
were abolished.
Discussion
The cardiovascular benefits exerted by estrogens have 
been widely described. For instance, in postmenopausal 
Figure 1. Effects of genistein and 17β-estradiol on cell viability and mitochondrial membrane potential of H9c2 cultured in physiological and peroxidative 
conditions. Effects of genistein (G) 10 pM, 100 pM, 10 nM, 100 nM, 1 µM for 30 min and 17β-estradiol (E) 10 pM, 100 pM, 10 nM, 100 nM, 1 µM for 30 min, 
on cell viability and mitochondrial membrane potential, are show in physiological (A) and (c) and peroxidative (B) and (d) conditions. c=control. Reported 
data are means ± SD of five independent experiments. *P<0.05 vs. c; #P<0.05 vs. H2O2 200 µM. Square brackets indicate significance between groups (§P<0.05).
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women coronary heart disease has been linked to loss of 
estrogen protection, and estrogen administration has been 
reported to be associated with reduced cardiovascular risk 
factors (10). Furthermore, in anesthetized pig, the administra-
tion of 17β-estradiol was shown to induce vasodilation through 
NO release (10).
Nevertheless, estrogen therapy has been associated with 
increased incidence of complications. For this reason, alterna-
tive agents related to estrogens, among which phytoestrogens, 
have gained wide attention (22). Thus, epidemiological studies 
have revealed low rates of cardiovascular diseases (cVd) 
among Asian populations whose diet is rich in phytoestro-
gens. This finding would suggest a plausible causal inverse 
relationship between phytoestrogens and cVd (13,23-26). 
However, up to-date, information about the cellular mecha-
nisms underlying the cardiovascular effects of phytoestrogens 
is scarce.
The results obtained with our study have shown, to the 
best of our knowledge, for the first time that genistein plays 
an important role in the modulation of cell viability, prolifera-
tion/migration, mitochondrial membrane potential and oxygen 
consumption in H9c2, cultured either in physiological or 
pathological conditions. In addition, cell cycle analysis revealed 
an increase in the percentage of H9c2 cultured in physiological 
conditions, in S phase in response to genistein. Moreover, in 
peroxidative conditions, a reduction of apoptosis and an 
Figure 2. Effects of genistein and 17β-estradiol on H9c2 proliferation in physiological (A) and peroxidative (B) conditions and H9c2 migration (c). 
Abbreviations are as in Fig. 1. Reported data are means ± SD of five independent experiments. *P<0.05 vs. c; #P<0.05 vs. H2O2 200 µM. Square brackets 
indicate significance between groups (§P<0.05).
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increase of S and G2/M phases was observed in H9c2 treated 
with genistein. Similar effects were observed in the presence of 
estradiol. Our findings regarding cell viability would not confirm 
those obtained by Gutiérrez-Venegas et al (27) who showed an 
absence of effects of genistein in H9c2. In those experiments, 
however, genistein was administered with lipopolysaccharide 
and for longer periods. By contrast, our data confirm previous 
results obtained in H9c2 cultured in an experimental setup, 
the chemical-induced hypoxic condition (28), which would be 
more similar to our experimental model.
The doses of genistein were comparable to the ones 
previously used and were in the range of nutritional concentra-
tions (29,30). Moreover, the effects of genistein were similar 
to those elicited by 17β-estradiol, which was administered 
in a concentration range that can commonly be found in 
menstrual or menopausal women (31,32). In addition, similar 
doses of estradiol affected calcium movements and modulated 
hypertrophic signalling in the same cellular model (33,34).
In our study, the use of specific inhibitors, allowed us to 
highlight the involvement of pathways related to Akt, ERK1/2, 
Figure 3. Effects of genistein and 17β-estradiol on cell cycle in H9c2 cultured in physiological (A) and peroxidative (B) conditions. cell cycle distribution 
was measured by flow cytometry using propidium iodide staining and quantitative analysis of apoptosis, G0/G1, synthesis, and G2/M phase is shown in a bar 
graph form. Abbreviations are as in previous figures. Reported data are means ± SD of five independent experiments. *P<0.05 vs. c; #P<0.05 vs. 200 µM H2O2. 
Square brackets indicate significance between groups (§P<0.05).
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Figure 5. Effects of genistein and 17β-estradiol on phosphorylated and total eNOS/β-actin (A) and iNOS expression (B) in H9c2 cultured in physiological and 
peroxidative conditions. Abbreviations are as in previous figures. Reported data are means ± SD of five independent experiments. *P<0.05 vs. c; #P<0.05 vs. 
H2O2 200 µM. Square brackets indicate significance between groups (§P<0.05).
Figure 4. Effects of genistein (A and B) and 17β-estradiol (c and d) on cell viability of H9c2 cultured in physiological (A and c) and peroxidative 
(B and D) conditions, in the presence/absence of various inhibitors. Abbreviations are as previous figures. F (fulvestrant 100 nM); G15 (100 nM); L‑NAME 
(100 nM); UO126 (100 nM); W (wortmannin 100 nM); SB (SB203580 100 nM). Reported data are means ± SD of five independent experiments. *P<0.05 vs. c; 
#P<0.05 vs. H2O2 200 µM; $P<0.05 vs. G; &P<0.05 vs. E. Square brackets indicate significance between groups (§P<0.05).
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and p38MAPK in the mechanisms of action of both genistein 
and 17β-estradiol on cell viability and mitochondrial membrane 
potential. Their involvement was also confirmed by western 
blot analysis. Those findings are in agreement with previous 
ones showing the role of the above kinases in the protective 
effects elicited by genistein and 17β-estradiol in H9c2 (30,35).
The observation of an improvement of mitochondrial 
membrane potential and oxygen consumption in response 
to genistein and 17β-estradiol is of particular relevance and 
could be involved in the mechanism of protection exerted 
by estrogens and phytoestrogens against peroxidation. Thus, 
mitochondrial membrane potential has been considered a 
good indicator of the energy status of the mitochondria and, 
above all, of cellular homeostasis. Interestingly, changes in 
mitochondrial membrane potential are reportedly correlated 
with cell survival or death through apoptosis (36-38).
Furthermore, the improvement of mitochondrial function 
could be at the basis of increased cell proliferation/migration 
observed in response to both genistein and estradiol up to 
100 nM. concerning this issue, data related to the phytoes-
trogens are quite new. Hence, previous findings collected in 
vascular smooth muscle cells or cardiac fibroblasts showed 
inhibitory effects elicited by genistein (39-41). Regarding estra-
diol, our results are in agreement with previous ones showing 
either an increase or decrease of cardiomyoblast proliferation 
at low and high estrogenic concentrations, respectively (42).
In H9c2 cultured in physiological conditions, estrogens 
and phytoestrogens were shown, for the first time, to acutely 
Figure 6. Effects of genistein and 17β-estradiol on reactive oxygen species (ROS) (A) and glutathione (GSH) (B) production in peroxidative conditions and 
oxygen consumption rate (OCR) (C) in physiological/peroxidative conditions by H9C2. Abbreviations are as in previous figures. NAC (N acetyl‑cysteine 
200 µM). Reported data are means ± SD of five independent experiments. *P<0.05 vs. c; #P<0.05 vs. H2O2 200 µM. Square brackets indicate significance 
between groups (§P<0.05).
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increase NO release. As observed for cell viability and mito-
chondrial membrane potential, those effects were related 
to the involvement of ERK1/2, p38MAPK and Ak-related 
pathways, which are well known to play a key role in eNOS 
activation (43-45). By contrast, in peroxidative conditions, 
the two agents reduced the excessive release of NO caused by 
hydrogen peroxide. These results are particularly relevant if 
we consider the different role played by NO. NO is synthe-
sized from L-arginine by three isoforms of NOS (46). These 
are the inducible and calcium-independent NOS (iNOS), the 
constitutive and calcium-dependent, neuronal NOS (nNOS) 
and the constitutive and calcium-dependent, endothelial NOS 
(eNOS) (47). It is notable that, while NO produced in low 
concentration, as in the case of the eNOS activation, would act 
as a messenger and cytoprotective factor via direct interactions 
with transition metals and other free radicals (48), the stimula-
tion of iNOS and NO overproduction could increase reactive 
nitrous species (RNS) formation and cause cellular death.
In the present study, eNOS phosphorylation was found to 
be increased by genistein and 17β-estradiol in H9c2 cultured 
in physiological conditions. By contrast, when H9c2 cardio-
myoblasts were subjected to peroxidation, eNOS activation 
was slightly decreased in comparison with the strong iNOS 
expression; this could explain the findings regarding NO 
production. Since these effects were counteracted by estro-
gens and phytoestrogens, the modulation of the imbalance 
of the various isoforms of NOS and NO release could be 
hypothesized to be at basis of the protective effects elicited by 
genistein and 17β-estradiol against peroxidation and increased 
cell death. Our findings are similar to those recently reported 
by Ma et al who showed a role for NO in the antiapoptotic 
effects of bioactive organosulfur compounds of garlic, such 
as allicin, in H9c2 (49). In addition, the biological actions of 
the polyphenol agent, licochalcone c, against oxidative stress 
injuries in H9c2 have been found to be related to the mainte-
nance of the balance between the constitutive and inducible 
Figure 7. Effects of genistein and 17β-estradiol on NO release by H9c2 cultured in physiological (A) and peroxidative (B) conditions and in the pres-
ence/absence of various inhibitors (C and D). Abbreviations are as in previous figures. Reported data are means ± SD of five independent experiments. 
*P<0.05 vs. c; #P<0.05 vs. H2O2 200 µM; $P<0.05 vs G; &P<0.05 vs. E. Square brackets indicate significance between groups (§P<0.05).
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isoforms of NOS (50). Finally, recent data by Zuo et al, have 
shown that Panax ginseng was able to protect cardiomyocytes 
against ischemic/reperfusion damage by triggering the cascade 
of the so-called reperfusion injury salvage kinase (RISK) 
pathways, which involves ERK1/2 and Akt, and the subse-
quent eNOS-related NO release modulation (51). Interestingly, 
the pretreatment of H9c2 with L-NAME, the non-selective 
NOS inhibitor, was able, not only to reduce the effects of 
the two agents on NO release, but also on cell viability and 
mitochondrial membrane potential.
It could therefore be hypothesized that a key role is played 
by NO as modulator of mitochondrial function in mediating 
the protective effects elicited by phytoestrogens and estrogens 
in H9C2. Our speculations are supported by previous findings 
showing an increased oxidative phosphorylation efficiency by 
NO and beneficial effects on mitochondrial matrix pH and 
mitochondrial membrane potential (52).
The protective effect of genistein and 17β-estradiol on 
the cardiomyoblast response to oxidative stress, has been 
confirmed by the analysis of intracellular ROS release and 
GSH production (53-56). Oxidative stress, which is caused 
by the accumulation of intracellular ROS or RNS, is one of 
the leading factors triggering cardiomyocyte apoptosis by 
affecting mitochondrial function. Moreover, ROS may have 
direct detrimental effects on cellular structure and function 
by modulating myocardial remodeling, which represents a 
risk factor for cVd. For this reason, inhibiting ROS produc-
tion or the enhancement of ROS scavenging could be used 
as a therapeutic strategy for treating cVd. Those species are 
generated constantly in vivo, and can cause oxidative damage 
to dNA, proteins and lipids resulting in cellular apoptotic 
death. Activation of the PI3K/Akt pathway in H9c2 cells can 
suppress apoptosis and promote cell survival (56). Therefore, 
the results we have obtained would suggest that both genis-
tein and 17β-estradiol can protect H9c2 from peroxidation 
through the modulation of mitochondrial function by the 
involvement of Akt pathway. Our data are in agreement with 
those obtained by Zuo et al regarding the role of ginseng in 
H9c2 (51) and are similar to what was found in other cell 
types (30,25,57-61).
The involvement of ERs and GPER receptors in the 
mechanisms of action of genistein and 17β-estradiol in 
H9C2 has been confirmed by using fulvestrant and G15. Our 
findings are in line with previous observations on the role 
of both estrogenic receptors in the cardiovascular effects of 
estrogens and phytoestrogens. In particular, although ERs are 
involved in the cardio-protection exerted by 17β-estradiol, 
its protective effects have been also described in the absence 
of ERs (62). Those findings lead to speculations about the 
existence of alternative receptors such as GPER and signal-
ling pathways involved in 17β-estradiol-mediated regulation 
of cardiovascular function. In particular, GPER activation 
leads to the downstream enhancement of signalling molecules, 
such as ERK1/2 and Akt (63). concerning genistein, our data 
regarding the role of GPER in the cardiac protective effects 
are quite new, since previous findings mainly involved the 
reproductive system.
In conclusion, this study has shown, to the best of 
our knowledge, for the first time that, genistein improves 
viability/proliferation and mitochondrial function of H9c2 
through mechanisms not so different from those suggested 
by the effects of estradiol. In particular, ERs and GPER 
receptors, the RISK pathway and the modulation of NO release 
by eNOS/iNOS could play a role in exerting their physiological 
effects and protection against peroxidation. These findings 
could be of clinical relevance for the management of cardio-
vascular disease in postmenopausal women, in which the use 
of phytoestrogens may be an alternative hormonal therapy for 
the amelioration of postmenopausal cVd.
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